{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+2+Mg+tablet",
    "query": {
      "intervention": "Estradiol 2 Mg tablet"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 105,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+2+Mg+tablet&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T17:25:11.318Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05646862",
      "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Bupropion",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2023-06-07",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 39,
      "location_summary": "Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05646862"
    },
    {
      "nct_id": "NCT00827632",
      "title": "Obesity, Oral Contraception, and Ovarian Suppression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ovarian Suppression"
      ],
      "interventions": [
        {
          "name": "Low dose formulation",
          "type": "DRUG"
        },
        {
          "name": "High dose formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 226,
      "start_date": "2006-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827632"
    },
    {
      "nct_id": "NCT00754325",
      "title": "Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2008-09",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-05-26",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 28,
      "location_summary": "Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754325"
    },
    {
      "nct_id": "NCT04309643",
      "title": "Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "CTP-543",
          "type": "DRUG"
        },
        {
          "name": "Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Concert Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2020-06-09",
      "completion_date": "2020-07-08",
      "has_results": false,
      "last_update_posted_date": "2020-07-16",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04309643"
    },
    {
      "nct_id": "NCT00394771",
      "title": "A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breakthrough Bleeding"
      ],
      "interventions": [
        {
          "name": "DR-1031",
          "type": "DRUG"
        },
        {
          "name": "Seasonale®",
          "type": "DRUG"
        },
        {
          "name": "Portia®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duramed Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 567,
      "start_date": "2006-10",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2013-07-26",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 50,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394771"
    },
    {
      "nct_id": "NCT00241449",
      "title": "A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 51,
      "start_date": "1998-11",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-06-06",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Fountain Valley, California • La Jolla, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241449"
    },
    {
      "nct_id": "NCT00357604",
      "title": "Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)",
          "type": "DRUG"
        },
        {
          "name": "Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2006-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2011-04-08",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357604"
    },
    {
      "nct_id": "NCT02392611",
      "title": "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors and Lymphomas"
      ],
      "interventions": [
        {
          "name": "Alobresib",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2015-03-16",
      "completion_date": "2017-10-11",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392611"
    },
    {
      "nct_id": "NCT05073237",
      "title": "Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Menopause",
        "Prediabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "conjugated estrogens/bazedoxifene (CE/BZA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 60 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2024-04-08",
      "completion_date": "2024-04-08",
      "has_results": false,
      "last_update_posted_date": "2024-05-10",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05073237"
    },
    {
      "nct_id": "NCT02922348",
      "title": "Hormone Replacement for Premature Ovarian Insufficiency",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Ovarian Insufficiency"
      ],
      "interventions": [
        {
          "name": "Hormone Replacement Therapy",
          "type": "DRUG"
        },
        {
          "name": "Combined Oral Contraceptives",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 45 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2016-03-01",
      "completion_date": "2018-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-09-23T17:25:11.318Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02922348"
    }
  ]
}